13 February 2019
Merck Animal Health Increases Facility Capacity and Capability in Millsboro, Delaware, With Significant Upgrades to its Manufacturing and Warehousing Operations
Increased Local Investment Builds Strength for the Future
to Better Meet Customer Demand
MILLSBORO, Del., February 13, 2019 – Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, today announced increased investment and expansion opportunities in its U.S. manufacturing and warehousing sites, namely Millsboro, Delaware. The company has expanded its manufacturing capacity and capabilities in Millsboro last year with additional expansion activities planned over the next few years.
“We are excited about the opportunity to bring capital improvements, expansion in our manufacturing capacity and capabilities, and advanced technology to our Millsboro facility, thereby, strengthening our footprint in the state and increasing our ability to fulfill customer demand for our portfolio of products,” said Bruce Lynch, Site Director, Merck Animal Health, Millsboro, Delaware. “Our Merck Animal Health business is making great strides in building our business for the future. That means we need to ensure our place as a leader in animal health with a substantial and sustainable U.S. facility footprint, which includes investment and expansion in our key facilities. As a leader in delivering innovative pharmaceuticals and vaccines to advance animal health and meet customer needs, this investment reflects our commitment in producing a range of animal health vaccines and pharmaceuticals for animal health diseases.”
Because of the company’s strong growth, broad product portfolio, and enhanced manufacturing capacity and capabilities, Merck Animal Health continues to explore ways in the U.S. and globally to improve existing facilities with upgraded equipment or technology, further expand its facilities with advanced technology platforms and increase capacity and capabilities in manufacturing and warehousing to meet the rapidly growing demand and flexibility for its vaccine and biologic products.
“We are working diligently to create new ways and processes to better serve our customers and strengthen our investment in expanding our manufacturing and warehousing capacity and capabilities so that we remain a valued partner to our customers through our reliability, flexibility and responsiveness,” said Scott Bormann, Vice President, North America Commercial Operations, Merck Animal Health. “Our investment in Millsboro positions our company for strong long-term growth and emphasizes our dedication to the Science of Healthier Animals®.”
Merck Animal Health is one of the largest poultry vaccine manufacturers worldwide, with products against most major pathogens and a focus on diseases affecting broilers, breeders and layers. The company continues to invest in expanding its manufacturing facilities around the world with a recent expansion of its manufacturing, packaging and warehousing facility for blending and filling of poultry vaccines at its site in Milton Keynes, United Kingdom.
The health and well-being of animals is the first and foremost priority of Merck Animal Health. The company strongly supports the responsible use of enhanced vaccine and pharmaceutical production platforms to improve and maintain the health of animals, as well as discovery of new tools to prevent, treat, and in some cases, even eradicate diseases.
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).